Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France
Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France. // The Breast. – URL: https://www.sciencedirect.com/science/article/pii/S0960977626002493?dgcid=rss_sd_all
Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France. The Breast. https://www.sciencedirect.com/science/article/pii/S0960977626002493?dgcid=rss_sd_all
“Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France.” The Breast.
@article{article67572,
title = {Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France},
journal = {The Breast},
url = {https://www.sciencedirect.com/science/article/pii/S0960977626002493?dgcid=rss_sd_all}
}
ABSTRACT Objectives The aim of this study was to determine whether certain cephalometric findings can predict the future need for orthognathic surgery (OS) in cleft lip (CL), cleft palate (CP), unilateral cleft lip and palate (UCLP),...